抗β淀粉样蛋白单克隆抗体在阿尔茨海默病中的应用OA

This review focuses on the clinical application of anti-amyloid β-protein(Aβ)monoclonal antibodies in Alzheimer's disease(AD).Following an overview of the disease characteristics and current therapeutic landscape,it examines the drug profiles,clinical efficacy,patient selection,adverse event management,and individualized dosing strategies of these agents.The approval of the anti-Aβ monoclonal antibodies lecanemab and donanemab marks a major breakthrough in etiology-directed treatment for AD.The 2 drugs can effectively clear cerebral Aβ deposits and delay cognitive decline.In clinical practice,patients should undergo indication screening and risk assessment before treatment to ensure efficacy and safety.Management of adverse reactions should focus on monitoring for amyloid-related imaging abnormalities and infusion-related reactions.Individualized treatment requires comprehensive consideration of comorbidities,characteristics of special populations,and concomitant medications.At present,the clinical application of anti-Aβ monoclonal antibodies continues to face challenges,including the need for further verification of efficacy and safety,a limited eligible population,and high treatment costs.Future efforts should optimize dosing regimens and diagnostic and treatment approaches and explore novel therapeutic targets and nonpharmacological interventions to promote a more diversified approach to AD treatment.